Thursday, May 29, 2025 5/29/2025

Development of a novel small molecule-based approach for accelerated fracture repair in the aging skeleton

Award Number: R44AR076882
ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

Development of a novel small molecule-based approach for accelerated fracture repair in the aging skeleton - PROJECT SUMMARY/ABSTRACT Approximately 6.3 million fractures occur in the United States each year, accounting for 16% of all musculoskeletal injuries and leading to well over 10 million hospital and physician offices visits. Up to 10% of fractures are recalcitrant and require surgical intervention for proper healing. The weakened bones in the growing geriatric population are contributing to the rising number of cases of this orthopedic problem and are projected to fuel demand for new, innovative solutions. According to the Department of Economic and Social Affairs, United Nations, Population Division, the number of people aged over 60 was 841 million in 2013 and is expected to reach 2 billion in 2050. Thus, the market is anticipated to witness a significant demand in coming decades. Cayman Chemical Company, Inc. seeks to address the unmet need by developing and commercializing a new small molecule based locally-administered drug-matrix combination for at-risk elderly fracture patients with delayed or nonunion fractures (DNFs). Cayman had discovered and patented a series of EP4 receptor agonists designed, synthesized, and screened for target potency and selectivity, cell activity, and metabolic and physicochemical properties amenable to rapid systemic clearance suitable for local administration. During Phase I of this project, Cayman selected the lead compound, KMN-159, that demonstrated osteogenic capacity in vitro and will serve as the active pharmaceutical ingredient (API) in the combination product. An osteoconductive mineralized collagen matrix (MCM) was functionalized with multiple doses of KMN-159, and the combination was evaluated in an accepted young rat femoral critical size defect model of nonunion fracture, demonstrating dose-dependent efficacy. During Phase II, Cayman will demonstrate dose-dependent efficacy of the combination in a model comparable to that used in the pilot study using young and old rats from the NIA rodent colony. Cayman will also initiate cGMP development of the API manufacture process, with which it will produce the release API batch that will be used for a GLP-compliant pivotal rabbit study. Cayman will combine the released API with a commercial 510(k)-approved MCM and demonstrate efficacy and safety in the GLP rabbit study.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2020	CAYMAN CHEMICAL CO INC	1180 E ELLSWORTH RD	ANN ARBOR	MI	48108	WASHTENAW	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	2	10/12/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2020	CAYMAN CHEMICAL COMPANY, INCORPORATED	1180 E ELLSWORTH RD	ANN ARBOR	MI	48108	WASHTENAW	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	2	8/26/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $750,058 )
2020	2020	CAYMAN CHEMICAL COMPANY, INCORPORATED	1180 E ELLSWORTH RD	ANN ARBOR	MI	48108	WASHTENAW	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	2	8/17/2020	NON-COMPETING CONTINUATION	$750,058
														Subtotal = $750,058

Issue Date FY: 2019 ( Subtotal = $728,311 )
2019	2019	CAYMAN CHEMICAL COMPANY, INCORPORATED	1180 E ELLSWORTH RD	ANN ARBOR	MI	48108	WASHTENAW	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	9/13/2019	NEW	$728,311
														Subtotal = $728,311

Grand Total All Awards = $1,478,369

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of a novel small molecule-based approach for accelerated fracture repair in the aging skeleton

Award Number: R44AR076882

ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer